Drug intelligence / Profile preview

RTY-822

Development stage: Preclinical
Lead developer: Rectify Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

RTY-822 is an orally administered small molecule drug developed by Rectify Pharma. It acts as a modulator of the ABCC6 protein, which is implicated in vascular calcification and kidney function. Preclinical studies have shown that RTY-822 improves kidney function and reduces vascular calcification in animal models of chronic kidney disease. The drug is being investigated primarily for the treatment of aortic and renal diseases, with its current development status in preclinical stages[1][2][10].

Targets

ABCC6 (ATP-binding cassette sub-family C member 6)

Beyond the preview

Go deeper on RTY-822.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RTY-822.

Explore the full profile